Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Scientist examines the result of a plaque assay, for article on gene therapy cure MLD

Researchers cure toddler of deadly metachromatic leukodystrophy (MLD) for first time in history

Gene therapy has cured 19-month-old Teddi Shaw of metachromatic leukodystrophy, making her the first NHS patient treated for this rare, fatal nervous system disease. After a single infusion of Libmeldy at Royal Manchester Children’s Hospital, she’s now running around, chattering away, and showing no signs of the illness that typically kills children before age eight. The treatment works by correcting a faulty gene in the child’s own stem cells, eliminating the disease at its root rather than managing it. Her family’s joy is tempered by grief — Teddi’s older sister was diagnosed too late for the therapy to help, fueling calls for newborn screening. It’s a glimpse of medicine’s next era: one-time cures for inherited conditions, if access and early detection can keep pace.

Abstract image with woman's face repeated, for article on psychedelics approved as medicines

Australia becomes world’s first country to officially recognize psychedelics as medicines

Psychedelic medicine just crossed a historic threshold — Australia is now the first country to give psychiatrists a legal pathway to prescribe psilocybin and MDMA as regulated treatments for PTSD and treatment-resistant depression. For patients who have cycled through every available option without relief, that’s a genuinely new door opening. The decision followed thousands of public submissions and a growing body of clinical evidence, including a landmark New Zealand Journal of Medicine study on psilocybin’s efficacy. It shows that political barriers — not just scientific ones — can eventually fall when evidence and public pressure align.\n\n—\n\n**Word count: 95**

Fungal infection under microscope, for article on pan-fungal vaccine

First vaccine to target deadly fungal infections passes preclinical tests

Fungal infections kill an estimated 1.6 million people every year, yet until now no vaccine has ever existed for any of the major culprits. Researchers at the University of Georgia have developed a single shot that trains the immune system to recognize all three deadliest fungal genera simultaneously — a feat never before demonstrated in peer-reviewed research. Crucially, it reduced illness and death in immunocompromised animals, the very people most at risk. For a disease category the WHO only recently recognized as a global emergency, this candidate offers the first real hope of prevention.\n\n*(Word count: 88)*

Vials of blood, for article on cancer diagnostics Africa, for article on Parkinson's blood test

Morocco becomes first African nation to produce its own cancer diagnosis tests

Morocco’s research foundation has developed cancer diagnostic tests made entirely in Africa—a breakthrough that promises to slash waiting times from weeks or months down to hours, and potentially cut costs in half. The leukemia test, already used on 400 patients, sidesteps the costly delays of importing kits from Europe or North America. Because results no longer need to travel abroad for interpretation, patients can receive treatment sooner when it matters most. This success builds on Morocco’s earlier COVID-19 test and positions African nations to control their own medical futures rather than depend on distant supply chains.\n\n**Word count: 95**

Vials and syringes in a lab, for article on not-for-profit drug access

Pfizer to sell all its drugs in 45 low-income countries at non-profit price

Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.

Cannabis being weighed, for article on legal cannabis dispensary, for article on Germany cannabis legalization

New York opens its first legal recreational cannabis dispensary

New York’s first legal recreational cannabis dispensary opened with a meaningful twist: the very first retail license went to Housing Works, a nonprofit that serves people with HIV, homeless New Yorkers, and the formerly incarcerated. Revenue from the shop will flow back into those social services, turning a newly legal market into direct support for communities hit hardest by the war on drugs. New York reserved its earliest licenses for nonprofits, people with past marijuana convictions and their families, women- and minority-owned businesses, and veterans, backed by a $200 million equity fund. It’s an ambitious bet that legalization can repair harm rather than just generate profit, and other states are paying close attention.